Retinitis pigmentosa is a group of inherited eye diseases that gradually steal vision, beginning with difficulty seeing at night and progressing over years to affect peripheral and eventually central vision. While there is currently no cure for most people living with this condition, treatments are evolving rapidly—from traditional approaches that help preserve remaining vision to cutting-edge therapies being tested in clinical trials around the world.

What Treatment Options Are Available Today?

When someone receives a diagnosis of retinitis pigmentosa, or RP as it is often called, understanding the available treatment options becomes crucial. Treatment for this condition focuses on several key goals: slowing the progression of vision loss when possible, managing symptoms that interfere with daily life, and helping individuals make the most of their remaining vision. The approach to treatment depends heavily on the stage of the disease, the specific genetic cause when known, and the individual patient’s needs and circumstances.

It’s important to recognize that retinitis pigmentosa encompasses a group of related disorders rather than a single disease. Because different genetic variations can cause RP, the progression and severity vary significantly from person to person. Some individuals experience slow, gradual vision changes over many decades, while others face more rapid deterioration. This variability means that treatment must be personalized, taking into account not just the medical aspects but also how the condition affects someone’s ability to work, navigate their environment, and maintain independence.

The landscape of RP treatment includes both standard approaches approved by medical societies and emerging therapies currently being investigated in clinical trials. Standard treatments have been used for years to support patients, while research into new therapies—including gene therapies, cell-based treatments, and innovative molecules—offers hope for more targeted interventions in the future. Each approach addresses different aspects of this complex condition, and many patients benefit from a combination of strategies.

Standard Treatment Approaches

The foundation of standard treatment for retinitis pigmentosa involves helping patients maximize and protect the vision they still have. This begins with ensuring proper refraction—the process of determining the correct prescription for glasses or contact lenses. As RP progresses, vision needs can change, making regular eye examinations essential. These exams typically occur annually and include visual field testing, which measures peripheral vision, and sometimes electroretinography or ERG, a specialized test that evaluates how well the retina responds to light.

One of the most discussed standard treatments involves vitamin supplementation, particularly vitamin A. Research has suggested that high daily doses of vitamin A palmitate—specifically 15,000 international units per day—may slow the progression of RP by approximately 2% per year in some patients. This effect, while modest, accumulated over many years could mean preserving useful vision for a longer period. However, this treatment comes with important considerations. Taking high doses of vitamin A over long periods carries potential risks, particularly to the liver. Patients pursuing this approach need regular monitoring, including annual checks of liver enzymes and vitamin A levels in the blood, to ensure safety.

Some healthcare providers recommend beta-carotene, which the body converts to vitamin A, as an alternative. Doses of 25,000 international units have been suggested. Additionally, research has explored other nutritional supplements. Docosahexaenoic acid, or DHA, is an omega-3 polyunsaturated fatty acid found in fish oil that acts as an antioxidant. Studies have shown correlations between patients’ DHA levels and their retinal function as measured by ERG. Some evidence suggests that higher levels of DHA might be associated with slower declines in vision, though more research is needed to confirm these benefits definitively.

Lutein and zeaxanthin are macular pigments—substances concentrated in the central part of the retina that the body cannot produce on its own but must obtain from diet. These compounds are thought to protect the macula from oxidative damage, a process where unstable molecules harm cells. Oral supplementation with lutein has been shown to increase macular pigment levels. While these supplements have been studied for age-related macular degeneration, their specific role in preventing cone photoreceptor death in RP is still being investigated. Recommended doses range from 6 to 20 milligrams per day.

Another important component of standard care involves protecting the retina from further damage. Eye care providers typically recommend that patients with RP wear ultraviolet or UV-blocking sunglasses when outdoors. UV radiation from sunlight can potentially accelerate retinal degeneration, and protecting the eyes from this exposure may help delay the onset or progression of symptoms. This is a simple, low-risk intervention that patients can implement immediately.

Beyond medical interventions, standard care places significant emphasis on low vision aids and vision rehabilitation. Low vision services help patients learn to use the vision they have more effectively. This might include training with magnifiers for reading, telescopic lenses for distance viewing, or electronic magnification systems. Many devices specifically designed to help with night vision difficulties are available through low vision clinics. Vision rehabilitation programs teach practical skills for daily living, such as navigating safely, organizing the home environment to reduce hazards, and using assistive technology like screen readers or voice-controlled devices.

For very advanced cases of retinitis pigmentosa where significant vision loss has occurred, an innovative option called a retinal prosthesis or artificial retina has been developed. This is essentially a bionic eye that can restore some degree of vision in people with severe vision loss. While not appropriate for everyone and still relatively new, this technology represents an important advancement for those with end-stage disease.

Emerging Therapies in Clinical Trials

The field of retinitis pigmentosa treatment is experiencing remarkable growth in research and development. Clinical trials—carefully controlled studies that test new treatments in human volunteers—are investigating multiple promising approaches. These trials progress through phases: Phase I trials primarily assess safety and determine appropriate dosing in small groups of participants. Phase II trials evaluate whether the treatment actually works and continues monitoring safety in larger groups. Phase III trials compare the new treatment against standard care or placebo in even larger populations to definitively establish effectiveness.

One of the most exciting areas of investigation involves gene therapy. Because RP is caused by genetic mutations—changes in the DNA instructions that cells use to build and maintain the retina—correcting these genetic errors at their source holds tremendous promise. The first gene therapy for an inherited retinal disease has already received FDA approval for patients with mutations in a gene called RPE65. This approval marked a historic milestone, demonstrating that genetic correction is possible for certain forms of RP.

Building on this success, researchers are developing gene therapies for other genetic forms of RP. For example, a gene therapy called laru-zova is being tested specifically for X-linked retinitis pigmentosa, or XLRP, which is caused by mutations in genes on the X chromosome, particularly the RPGR gene. In a Phase 2 clinical trial called DAWN, 15 male patients who had previously received the treatment in one eye had their second eyes treated. The results showed an average improvement of 16 letters on an eye chart—approximately 3 lines—in low luminance visual acuity, which measures the ability to read letters in dim light. Patients also showed improvements in microperimetry, a test that measures how sensitive different parts of the retina are to light. The company conducting this research has completed enrollment in a larger Phase 2/3 trial called VISTA, with results expected in 2026.

Gene therapies work by delivering a correct copy of the mutated gene into retinal cells. This is typically accomplished using a modified virus that cannot cause disease but can enter cells and deliver genetic material. Once inside, the correct gene provides instructions for making the protein that was missing or defective, potentially slowing or stopping further retinal degeneration.

Another innovative approach being tested involves RNA therapies, specifically antisense oligonucleotides. These are short pieces of genetic material designed to modify how genes are read and used by cells. Two RNA therapies have advanced into clinical trials: sepofarsen for people with a specific form of Leber congenital amaurosis (a severe inherited retinal disease related to RP) caused by mutations in the CEP290 gene, and ultevursen for people with mutations in exon 13 of the USH2A gene, which causes Usher syndrome—a condition combining RP with hearing loss.

An oral medication approach is also under investigation. An antioxidant called NACA, or N-acetylcysteine-amide, is designed to protect retinal cells from oxidative stress—damage caused by unstable molecules that harm cell structures. In a Phase 2 clinical trial in Australia for people with Usher syndrome, NACA reduced photoreceptor loss by 50 percent compared to placebo. This represents a significant potential for slowing vision loss. The treatment works by neutralizing harmful molecules and protecting cellular components from damage. An international Phase 3 trial is also being launched to test NAC, the original FDA-approved formulation of N-acetylcysteine.

Researchers have also identified a specialized antibody called a nanobody that may lead to treatments for forms of RP caused by mutations in the rhodopsin gene. Rhodopsin is a crucial light-sensing molecule in rod photoreceptors, and mutations in this gene cause autosomal dominant RP, meaning inheriting just one mutated copy from one parent is enough to cause disease. The nanobody works by binding to rhodopsin molecules and potentially stabilizing them or modulating their function, preventing the toxic effects that mutated rhodopsin can have on photoreceptor cells.

Stem cell therapy represents another frontier in RP treatment. A phase 1 clinical trial at UC Davis Health demonstrated that CD34+ stem cells—specialized cells that can develop into various cell types—can be safely isolated from a patient’s own bone marrow and injected into their eyes. These cells may offer therapeutic benefits, though the study was primarily designed to assess safety. The concept behind stem cell therapy is that these cells might protect remaining photoreceptors from dying, potentially by releasing beneficial factors that support cell survival, or in some cases, by replacing lost cells.

Clinical trials for RP are being conducted in multiple locations worldwide, including the United States, Europe, Australia, and other regions. Patient eligibility varies by study but often depends on having a confirmed genetic diagnosis, being within a certain age range, having specific levels of remaining vision, and not having other eye conditions that would interfere with the study. Genetic testing plays an increasingly important role, as many emerging therapies target specific genetic mutations. Knowing the exact genetic cause of someone’s RP can open doors to mutation-specific treatments and help predict how the disease might progress.

Most common treatment methods

• Vitamin and nutritional supplementation
  • Vitamin A palmitate at 15,000 international units daily, which may slow progression by about 2% per year, though requiring liver monitoring
  • Beta-carotene at 25,000 international units as an alternative to vitamin A
  • Docosahexaenoic acid (DHA), an omega-3 fatty acid that may correlate with better retinal function
  • Lutein and zeaxanthin, macular pigments that may protect against oxidative damage, at doses of 6-20 mg daily
• Vision protection and aids
  • UV-blocking sunglasses to protect the retina from potentially harmful ultraviolet radiation
  • Low vision aids including magnifiers, telescopic lenses, and electronic magnification systems
  • Vision rehabilitation training to learn skills for daily living and safe navigation
  • Assistive technology such as screen readers, voice-controlled devices, and specialized apps
  • Retinal prosthesis (artificial retina or bionic eye) for people with very advanced vision loss
• Gene therapy
  • FDA-approved gene therapy for RPE65 mutation-associated retinal dystrophy
  • Laru-zova gene therapy for X-linked RP caused by RPGR mutations, showing improvements in low-light vision in Phase 2 trials
  • Investigational gene therapies targeting other specific genetic mutations that cause RP
• RNA-based therapies
  • Sepofarsen, an antisense oligonucleotide for CEP290 mutations
  • Ultevursen for USH2A exon 13 mutations causing Usher syndrome
• Antioxidant therapies
  • NACA (N-acetylcysteine-amide), an oral antioxidant that reduced photoreceptor loss by 50% in Phase 2 trials for Usher syndrome
  • NAC (N-acetylcysteine) being tested in international Phase 3 trials
• Stem cell therapy
  • CD34+ stem cells isolated from patient’s own bone marrow and injected into the eye, shown to be safe in early-stage trials
• Specialized molecules
  • Nanobodies targeting rhodopsin for rhodopsin-associated autosomal dominant RP

Living with Retinitis Pigmentosa

Beyond medical treatments, managing life with retinitis pigmentosa requires practical adaptations and emotional support. The progressive nature of vision loss means that needs change over time, and developing coping strategies early can significantly improve quality of life. Many people with RP report that maintaining a positive outlook, using humor, and building strong social support networks are among the most valuable tools for dealing with the challenges of vision loss.

Practical strategies for daily living include optimizing home lighting with bright, even illumination throughout living spaces, as this helps compensate for reduced light sensitivity. Using color contrast—for example, marking light switches, stair edges, or kitchen items with contrasting colors—makes these objects easier to locate and identify. Organizing the home consistently so that items always have designated places reduces the need to search visually for things. Learning to navigate with a white cane or service animal can restore independence and confidence when moving through unfamiliar environments.

Technology offers increasingly sophisticated solutions. Smartphones and tablets include built-in accessibility features such as screen magnification, high-contrast displays, voice control, and screen readers that speak text aloud. Specialized apps can help with tasks ranging from identifying objects and reading printed text to navigating public transportation. These tools continue to improve, offering people with RP more options for maintaining independence.

Occupational therapists who specialize in vision rehabilitation can teach specific techniques for performing activities of daily living safely and efficiently despite vision loss. This might include methods for cooking, personal care, managing medications, and handling finances. Mobility specialists provide training in safe travel techniques, both indoors and outdoors. Many communities offer these services through vision rehabilitation agencies or government programs for people with visual impairments.

The workplace presents unique challenges that often require accommodations. Employers are legally required in many jurisdictions to make reasonable adjustments for employees with disabilities. For someone with RP, this might include flexible working hours to allow travel during daylight, screen-reading software, documents provided in accessible formats, adequate lighting, and a clear, uncluttered workspace to facilitate safe movement. Some individuals benefit from specialized equipment or services funded through programs like Access to Work.

Driving is often affected as RP progresses, particularly when peripheral vision narrows or night vision deteriorates. Regulations require drivers to inform licensing authorities about vision conditions, and there are minimum visual field requirements for driving. Many people with RP reach a point where driving is no longer safe or legal, which can be emotionally difficult but is essential for everyone’s safety. Planning for alternative transportation and building skills in using public transit, ride services, or paratransit can ease this transition.

Emotional and psychological support is crucial. Vision loss from RP can affect self-esteem, independence, career prospects, relationships, and mental health. Feelings of grief, frustration, anxiety, or depression are common and valid. Support groups, whether in-person or online, connect people with others facing similar challenges, providing practical advice and emotional understanding. Professional counseling or therapy can help individuals process the emotional impact of progressive vision loss and develop healthy coping mechanisms. Family members and friends also benefit from education about RP and guidance on how to provide support without undermining independence.